There is growing evidence for the antidepressant effects of psychedelics, yet the mechanism underlying these effects are still a mystery. Igor Magaraggia and Rudy Schreiber (of PIM) have suggested a hypothetical model of psychedelics therapeutic mechanism. "After investigating what psychedelics do at the molecular, cellular, and behavioural level, we have suggested a hypothetical model that… Continue reading Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach
New publication out now, in which we used an ultra‐high field multimodal brain imaging approach, and showed that in occasional cannabis users, acute THC administration increased striatal glutamate and decreased functional connectivity in the reward system, which were associated with increases in subjective high and decreases in sustained attention. Such changes were absent in chronic… Continue reading Reduced responsiveness of the reward system is associated with tolerance to cannabis impairment in chronic users
New publication out now, examining the accuracy of two commonly used point-of-collection testing devices in detecting oral fluid THC. Tests were performed at fixed intervals over 3 hours, yielding a total of over 300 tests. Both devices produces a surprisingly high number of false positives and false negatives. By 180 min, all samples contained less… Continue reading Detection of Δ9 THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: an evaluation of two point-of-collection testing devices
Most street cannabis contains large quantities of THC, the chemical in cannabis that gets people ‘high’, but there is increasing use of medicinal products that also contain CBD, a non-intoxicating cannabinoid with promising therapeutically potential. It has often been proposed that administering CBD may reduce some of the impairment caused by THC. To test this,… Continue reading Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
March 25, 2019. Researchers from IMIM (Barcelona) and our department employed the quantification of monoamine neurotransmitters and steroid hormones in brain tissue and blood of rats to predict the pharmacological similarity of NPS to classical drugs of abuse. The metabolomics approach in animals improves the speed of NPS classification.